NovaGo Therapeutics

1. Executive Summary (Confidence: High)

Founded in 2015 as a spin-off from the University of Zurich, NovaGo Therapeutics is a pioneer in the field of neuro-regeneration. The company’s core strategy revolves around its lead drug candidate, NG004, a human monoclonal antibody currently in a First-in-human (FIH) Phase 1b trial known as "SPROUT". NovaGo addresses a critical unmet medical need: the restoration of motor and sensory function after spinal cord injury (SCI), for which no effective restorative therapy currently exists. By leveraging a strategic partnership with Neurimmune AG for antibody discovery, NovaGo has developed a high-affinity therapy that targets the biological "brakes" on nerve growth, aiming to transform SCI from a permanent disability into a treatable condition.